Gene Signature Predicts Ovarian Cancer Survival
Using DNA microarray, scientists have determined a 93-gene signature called the Chemotherapy Response Profile (CRP) that can distinguish between ovarian cancer patients with unfavorable versus favorable overall survival. A patient’s prognosis could be further defined by combining the Ovarian Cancer Prognostic Profile (OCPP) with the CRP. The CRP may help clinicians figure out who will respond best to chemotherapy.
Stephen A. Cannistra, MD, director of gynecologic oncology at Beth Israel Deaconess Medical Center (BIDMC) and professor of medicine at Harvard Medical School:
Being able to identify the expression pattern of these genes from the original tumor sample [i.e. whether genes were turned on or turned off] provides us with valuable information about a patients prognosis as this type of information cannot always be obtained from standard clinical features, such as tumor grade or residual disease status. And with the identification of each new gene expression profile, we come one step closer to eventually being able to develop treatments tailored to individual ovarian cancer patients.
Journal of Clinical Oncology, Vol 23, No 31 (November 1), 2005
Newswise, November 3, 2005
Related Stories
POSTED IN: Genetics of Disease
.gif)
0 opinions for Gene Signature Predicts Ovarian Cancer Survival
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: